Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

HEMORRHAGIC VASCULITIS AND RETINOPATHY HERALDING AS AN EARLY SIGN OF BACTERIAL ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION.

Conrady CD, Feistmann JA, Roller AB, Boldt HC, Shakoor A.

Retin Cases Brief Rep. 2017 Jun 7. doi: 10.1097/ICB.0000000000000601. [Epub ahead of print]

PMID:
28594738
2.

Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

Wall M, Johnson CA, Cello KE, Zamba KD, McDermott MP, Keltner JL; NORDIC Idiopathic Intracranial Hypertension Study Group.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):805-12. doi: 10.1167/iovs.15-18626.

3.

Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.

Wall M, Falardeau J, Fletcher WA, Granadier RJ, Lam BL, Longmuir RA, Patel AD, Bruce BB, He H, McDermott MP; NORDIC Idiopathic Intracranial Hypertension Study Group.

Neurology. 2015 Sep 1;85(9):799-805. doi: 10.1212/WNL.0000000000001896. Epub 2015 Aug 5.

4.

Reply: To PMID 24667550.

Feistmann J.

Retina. 2014 Dec;34(12):e43. doi: 10.1097/IAE.0000000000000395. No abstract available.

PMID:
25407238
5.

Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features.

OCT Sub-Study Committee for NORDIC Idiopathic Intracranial Hypertension Study Group, Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith MJ, Sibony P, Plumb K, Wang JK, Werner JS.

Invest Ophthalmol Vis Sci. 2014 Nov 4;55(12):8173-9. doi: 10.1167/iovs.14-14961.

6.

Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability.

OCT Sub-Study Committee for NORDIC Idiopathic Intracranial Hypertension Study Group, Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith M, Sibony P, Plumb K, Wang JK, Werner JS.

Invest Ophthalmol Vis Sci. 2014 Nov 4;55(12):8180-8. doi: 10.1167/iovs.14-14960.

7.

Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.

NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ.

JAMA. 2014 Apr 23-30;311(16):1641-51. doi: 10.1001/jama.2014.3312.

8.

The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.

Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, McDermott MP; NORDIC Idiopathic Intracranial Hypertension Study Group.

JAMA Neurol. 2014 Jun;71(6):693-701. doi: 10.1001/jamaneurol.2014.133.

9.

The idiopathic intracranial hypertension treatment trial: design considerations and methods.

Friedman DI, McDermott MP, Kieburtz K, Kupersmith M, Stoutenburg A, Keltner JL, Feldon SE, Schron E, Corbett JJ, Wall M; NORDIC IIHTT Study Group.

J Neuroophthalmol. 2014 Jun;34(2):107-17. doi: 10.1097/WNO.0000000000000114.

PMID:
24739993
10.

Bimanual intraocular lens rescue with transconjunctival scleral fixation.

Feistmann JA, Prasad S, Gentile RC, Kasuga DT, Bhullar SS, Joshi DD.

Retina. 2014 Apr;34(4):812-5. doi: 10.1097/IAE.0000000000000101. No abstract available.

PMID:
24667550
11.

PRK-pTK as a treatment for a patient with Thygeson's superficial punctate keratopathy.

Goldstein MH, Feistmann JA, Bhatti MT.

CLAO J. 2002 Oct;28(4):172-3.

PMID:
12394540

Supplemental Content

Loading ...
Support Center